| |
|
Form Serial Number: |
DA20240419E00315
(Amendment to DA20240110E00503)
|
| 1.
Date of relevant event: |
22/12/2023
(dd/mm/yyyy)
|
| 2.
Date when director became aware of the relevant event/ interest in the shares (if later): |
(dd/mm/yyyy)
|
| 3.
Stock code: |
02511 |
| 4.
Name of listed corporation: |
HighTide Therapeutics, Inc. - B |
| 5.
Class of shares: |
Ordinary Shares |
| 6.
Number of issued shares in class: |
514,770,668 |
| 7.
Name of director (English) as printed on HKID Card/Passport: |
| (Surname) |
Li |
| (Other names) |
Li |
|
|
|
| 10.
Name of director (Chinese): |
李鋰 |
| 11.
Chinese Character Code as printed on HKID Card: |
|
| |
| 24.
Details of relevant event: |
|
|
Brief description of relevant event
|
Capacity in which shares were/are held
|
Number of shares bought/sold or involved
|
Currency of transaction |
On Exchange
|
Off Exchange
|
|
Before relevant event
|
After relevant event
|
Highest price (per share)
|
Average price (per share)
|
Average consideration (per share)
|
Consideration code
|
| Long position |
| 1701 | Miscellaneous
On listing of the corporation or a class of shares of the listed corporation |
|
|
| 2201 | Interest of corporation controlled by you |
|
121,515,210 |
|
|
|
|
|
| Short position |
|
|
|
|
|
|
|
|
|
| |
|
| 25.
Total shares in listed corporation immediately before the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 20,252,535 | 24.06 |
|
| |
| 26.
Total shares in listed corporation immediately after the relevant event: |
| | Total number of shares | Percentage figure (%) |
| Long position | 121,515,210 | 23.61 |
|
| |
| 27.
Capacity in which interests disclosed in Box 26 are held: |
| Code describing capacity | Number of shares |
| 2201 | Interest of corporation controlled by you |
| |
|
| |
| 28.
Further information in derivative interests in listed corporation : |
| Derivatives code |
Exercise period (dd/mm/yyyy) |
Consideration - if derivatives granted by listed corporation |
Number of shares |
| | | Begins | Ends | Currency | Price for grant | Currency | Exercise price | Currency | Price on assignment | |
| | | | | | | | | | | |
|
| |
| 29.
Further information in relation to interests of children under 18 and/or spouse: |
| Child/Spouse | Name of child/spouse | Number of shares |
| | |
|
| |
| 30.
Further information in relation to interests of corporations controlled by Director: |
| Name of controlled corporation | Address and place of incorporation | Name of controlling person | % control | Direct interest (Y/N) | Number of shares |
| Shenzhen Leren Technology Co., Ltd. | 27C, Block E, Portofino Swan Castle, No.2 Xiangshan Middle Street, Shahe Subdistrict, Nanshan District, Shenzhen, PRC | Li Li | 99.00 | N | |
| Urumqi Feilaishi Equity Investment Co., Ltd. | 2015-555, Cyberport Building, No. 258 Gaoxin Street, Urumqi High-tech Industrial Development Zone (New District), Xinjiang, PRC | Li Li | 100.00 | N | |
| Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | No. 21 Langshan Road, Nanshan District, Shenzhen, People’s Republic of China | Li Li | 62.90 | Y | |
| Hepalink (Hong Kong) Limited | 47/F Sun Hung Kei Centre, 30 Harbour Road, Wanchai, Hong Kong | Shenzhen Hepalink Pharmaceutical Group Co., Ltd. | 100.00 | N | |
| Hepalink Healthcare Partners I L.P | 89 Nexus Way, Camana Bay, Grand Cayman, KY1-9009, Cayman Islands | Hepalink (Hong Kong) Limited | 100.00 | N | |
| Hepalink Biotechnology II Limited | 11/F Central Tower 28 Queen's Road Central, Central, Hong Kong | Hepalink Healthcare Partners I L.P | 100.00 | Y | |
|
| |
| 31.
Further information in relation to interests held by Director jointly with another person: |
| Name of joint shareholder | Address | Number of shares |
| | |
|
| |
| 32.
Further information from a director who is a trustee, or beneficiary of a trust, or a person who has set up a Discretionary Trust: |
| Names of Trust | Address | Status code | Number of shares |
| | | |
|
| |
| 33.
Further information from a party to an agreement under Section 317 (Please see Notes for further information required): |
| Names of other parties | Address | Number of shares |
| | |
| Total number of shares in which a director is interested under sections 317 and 318 | |
|
| |
| 34.
Supplementary information: |
The changes of the percentage and the total number of shares in which Mr. Li Li interested in, from 24.06% to 23.61% and from 20,252,535 to 121,515,210, respectively were the result of the completion of the capitalization issue, the repurchase of shares from the 2023 ESOP platform and global offering on 22 December 2023, which was the date the shares of HighTide Therapeutics, Inc. were listed on the Main Board of the Stock Exchange of Hong Kong Limited.
|
| 35.
Log/Serial Number of the previous form: |
DA20240110E00503
|
| 36.
Number of concert party document(s) under section 317 attached/uploaded: |
|
|
Date of filing this Form 3A: |
19/04/2024
(dd/mm/yyyy)
|
| |